Showing posts with label David Sweanor. Show all posts
Showing posts with label David Sweanor. Show all posts

Wednesday, June 23, 2021

Matt Myers in 2003 and Today: A Pertinacious Tobacco Prohibitionist

 

Matthew Myers is a founder of the highly influential Campaign For Tobacco-Free Kids (CTFK), where he has served as president for over 20 years (here).  He claims to have “participated in virtually every major US tobacco-related legislative effort” and to have “led the effort that resulted in 2009 in the US Food and Drug Administration being given authority … over tobacco products.”

Myers and his organization are warriors for tobacco prohibition and staunch opponents of all forms of tobacco harm reduction (THR). 

At a 2003 congressional hearing titled, “Can Tobacco Cure Smoking? A Review of Tobacco Harm Reduction,” witnesses included the U.S. Surgeon General, the chairman of the Federal Trade Commission and Myers.  David Sweanor and I testified in support of THR.

Interestingly, Myers actually endorsed THR in his testimony, with a caveat.  He insisted that Congress

“grant the Food and Drug Administration comprehensive regulatory authority over all tobacco products. If we want to do harm reduction based on science, not rhetoric; if we want to make the truism that knowledge is power, then we will insure that there is a government agency that has regulatory authority over the product so that we will know and consumers will know what is in that product; so that we will know and consumers will know truthfully not just what the manufacturers want us to know but the truth, the full truth about the relative harmful effects of those products.” 

This was not an isolated statement.  In his oral and written testimony, he repeatedly expressed support for FDA-supervised THR.  Here is another excerpt:

“A discussion about harm reduction has to begin with a discussion about providing the FDA with the kind of authority that is necessary to protect consumers, verify claims, and require that all reasonable steps are taken to reduce the harm caused to smokers. Is there a role for smokeless tobacco in a comprehensive effort to reduce the death toll from tobacco overseen by the FDA? No one has the information to make that decision today. The FDA should be open to all strategies that are scientifically based and that will save lives. The decision about what role smokeless tobacco plays in that overall scheme is a decision that can only be made by the FDA after it has all of the relevant information before it.” 

Kentucky Congressman Ed Whitfield posed this question to Myers: “So is it your position that if the U.S. had a similar regulatory system that you would have no objection to products like snus or Revel?”

Myers responded, “If the U.S. had a comprehensive regulatory system, then scientists with full knowledge about the product would be able to make appropriate comparative science claims.”

Fast forward to 2019.  FDA tobacco regulation had been in effect for a decade, operating according to the legislative framework that Myers says he engineered.  This includes an onerous application pathway for manufacturers to convince the agency that their smoke-free products are safer than cigarettes.  Despite the seemingly impossible task of proving a negative, Swedish Match obtained modified risk status from the FDA for its General snus brand, allowing the company to tell smokers that “Using General Snus instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” Myers had testified against the application at an FDA hearing. 

In 2020, the FDA granted Philip Morris International modified risk status for its IQOS heat-not-burn tobacco, allowing the company to tell smokers that “Scientific studies have shown that switching completely from conventional cigarettes to the IQOS system significantly reduces your body’s exposure to harmful or potentially harmful chemicals.”

Myers and other tobacco prohibitionists were apoplectic about the IQOS decision, characterizing it as “a dangerous precedent that puts kids and public health at risk”, “making [kids] guinea pigs in a Philip Morris marketing experiment,” and repeating “an egregious error the FDA has made in the past” [with General Snus].  The groups’ press release concluded that “The FDA should have denied Philip Morris’ application in its entirety.” 

Make no mistake: Myers is a tobacco prohibitionist.  He gave lip service to THR in 2003, feigning support for THR contingent upon FDA regulation, as he expected to make it nearly impossible for manufacturers to convince the FDA that they had safer smoke-free products.  When companies twice succeeded, he reneged on his Congressional testimony and trashed the FDA. 

Sadly for Myers and CTFK, more smoke-free products will be approved by the FDA.  Camel Snus and Copenhagen moist snuff are already in the review pipeline, and it’s just a matter of time before dozens or more e-cigarettes, vapor products and nicotine pouches obtain safer FDA status. 

  

Wednesday, September 11, 2019

Tobacco Companies’ Best Friends


Anti-tobacco activists portray themselves as enemies of “Big Tobacco,” so they naturally characterize the current panic about vaping among American teens as a new campaign by the industry.  This is fundamentally wrong, according to David Sweanor, a veteran anti-smoking advocate and chair of the advisory board for the Center for Health Law, Policy and Ethics at the University of Ottawa.  In the following guest blog, Sweanor suggests that the war against vaping is cigarette manufacturers’ best hope for a lucrative future.

The presence of the tobacco industry plays a huge role in discussions on tobacco harm reduction and disruptive technology, but I have long found that those who think they are that industry’s greatest enemies are often among its biggest enablers. Yet understanding the fundamentals in play should not be so hard.

We can start with what the financial markets appear to think of the state of these companies, which is seen in the 5-year stock price charts at left. In early 2017, the combined value of the FT500 tobacco companies (PMI, BAT/Reynolds, Altria, Japan Tobacco, Imperial and ITC) surpassed US$700 billion. That was a continuation of a longstanding skyward march of these companies as they benefitted from their ‘nicotine maintenance monopoly’ and raised prices in a cartel-like fashion.

Recently the combined value was down to US$372 billion. In looking at their stock charts we can see clearly when disruption started to bite.

This makes sense when we consider that those valuations are the present value of future anticipated earnings. So long as the companies can, as in the US, make cigarettes for 28 cents a pack and sell them, pre-taxes etc., for over $2.00, and keep raising their prices aggressively, and price elasticity is low, it is a licence to print money. Regulatory barriers thwarting competition keep them secure.

But just as OPEC’s cartel invited alternative sources of energy and taxi cartels created an opportunity for Uber, the nicotine market has long been at risk of disruption, of true competition breaking out. The global cigarette market, at well over $US800 billion annually, huge profit margins, high tax burdens putting them at a price disadvantage, and unhappy customers, creates a tempting target. Regulations, public misinformation, actions by self-styled anti-tobacco groups, and technological challenges protect the cartel. But that protection is no longer assured and buying shares in Big Tobacco today starts to look a bit like buying into New York City taxi medallions just as Uber was getting launched.

The idea that cigarette companies welcome this disruption flies in the face of their stock prices. Yet many in the tobacco control field seem convinced that whatever happens with new technology Big Tobacco will win because, well, they have long dominated the market. Leaving aside that the market apparently disagrees, this is worth thinking about. Disruption has hit a great many businesses over a very long time. Would anyone care to list all the market-dominating companies that did well from such disruption? They typically get blown away, and for very good reasons. They are large, bureaucratic and risk-averse, and have much to lose if they make mistakes. They also typically lack the expertise in the emerging technologies and are held back by those in the company who are committed to the status quo. Meanwhile, lots of start-ups can compete for the emerging market with little to lose but huge upside if they are ultimate winners.

Horse breeders did not come to dominate the tractor business, nor horseless carriages. IBM missed out on software, Microsoft on social media, the Yellow Pages on internet search, NYC taxi medallion owners were not the backers of Uber. Then there were makers of rotary dial phones, beat by the likes of Motorola, in turn beaten by the likes of Nokia, which was trounced by BlackBerry, which in turn lost out to Samsung and Apple.  The list of big, established, market-dominating companies ‘doing a Kodak’ is very, very long.

Also, if Big Tobacco really wanted to facilitate a rapid transition to low risk products they would act very differently. They are, after all, in possession of the best market intelligence. They know what happens when vape products compete directly with cigarettes. They know how many smokers would seriously try to switch if adequately informed about relative risks, and they know how things like risk-proportionate regulation and taxation is likely to impact the markets. But they stay pretty quiet.

I think it is helpful to think of Big Tobacco and alternative nicotine the way we would think of the House of Saud and alternatives to fossil fuels. Big Tobacco must prepare as best they can for a market they think is fundamentally changing. They must sound like they are very supportive, for public relation and legal liability reasons. But the slower the transition, the longer they can reap the rewards of their exceedingly lucrative cartel.

Substituting market intelligence for the current ‘if they seem to want to do it, we will oppose it’ thinking, and the application of some strategy could lead to some quite extraordinary breakthroughs.




Wednesday, July 12, 2017

The Illogic of Condoning Vaping & Condemning Smokeless – Both Are Safer for Smokers



While many American tobacco researchers and policy experts have, of late, moved to endorse reasonable regulation of e-cigarettes and vaping, most persist in condemning smokeless tobacco products, which have been proven to be nearly harmless.  It is irrational to support one and prohibit the other, when both are legitimate harm reduction options for smokers.

The illogic of this dual position is displayed in the work of Dr. Dorothy Hatsukami, a prestigious tobacco researcher, author of 250 published articles (here) and recipient of tens of millions of dollars in NIH funding (available here, including $13 million to study reducing nicotine in cigarettes).  Dr. Hatsukami recently signed a letter to FDA Commissioner Scott Gottlieb (here) and published an article in Tobacco Control (here).

In the letter to the commissioner, Dr. Hatsukami applauded his “openness to the concept of tobacco harm reduction…There is already a considerable body of science and experience suggesting that a harm reduction approach…could yield substantial and highly cost-effective public health benefits…at this time we do not believe that the current regulatory framework for the low-risk nicotine products such as e-cigarettes and smokeless tobacco is appropriate or will deliver the substantial public health benefits we hope and expect FDA’s oversight will bring.”  The letter encouraged the FDA to regulate tobacco products according to risk and to “support informed choice through truthful communication of risk.”

However, in her Tobacco Control commentary, Dr. Hatsukami took a contrary view, fully endorsing the FDA’s proposed standard for NNN, which I have eviscerated here and here.  She wrote, “If [FDA] puts the proposed rule into effect, it would be a significant and important step towards minimising the harms from smokeless tobacco use.”  Surprisingly, she asserted that “the risk for oral cancer is considerably higher for smokeless tobacco users,” and cited a federal study documenting that American men who dip or chew tobacco have no mouth cancer risk (here).

Notably, other signatories to the Gottlieb letter are genuine tobacco harm reduction advocates who have endorsed the substitution of smoke-free tobacco by smokers.  They include Clive Bates of the UK and Canada’s David Sweanor, who filed a comment (here) labeling the NNN rule “reckless and pointless.”  American signatories who are on record about the relative safety of smokeless are Sally Satel (here and here), Kenneth Warner (here and here), David B. Abrams (here) and Raymond S. Niaura (here).